Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06342609
Other study ID # 32857-01-EKSTROM
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date March 15, 2023
Est. completion date September 7, 2024

Study information

Verified date March 2024
Source Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized double-blind, placebo-controlled, investigator-initiated trial that compares Colchicine 0.5mg/day with placebo, among patients with stable CAD. Subjects will be educated to maintain medication compliance with other prescribed medications.


Description:

The goal of this study is to evaluate whether treatment with Colchicine results in greater change of low attenuation plaque volume from baseline level when compared to placebo in subjects with stable Coronary Artery Disease (CAD). The Primary objective of the study is to determine progression rates of low attenuation plaque under influence of Colchicine as compared to placebo. The study will also look to determine effects of Colchicine on the morphology and composition non -calcified coronary plaque, progression of total plaque volume, progression of high vulnerability features of plaque and to assess whether these effects are modulated by a change in HsCRP and other markers of inflammation (HsCRP, IL-6, IL-1α, IL-1β, IL-18) as well as the effect on Pericoronary adipose tissue (PCAT) and Epicardial adipose tissue (EAT) volume and well as on the endothelial function.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 84
Est. completion date September 7, 2024
Est. primary completion date September 7, 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 85 Years
Eligibility Inclusion Criteria: 1. Age 30-85 years 2. Proven coronary artery disease; as evidenced by coronary angiography, CT coronary angiography or a Coronary Artery Calcium Score (Agatston score >400). 3. Clinically stable for at least six months 4. Patients should have no major competing co-morbidities or contra-indication to colchicine therapy 5. Patients must be considered to be compliant with their usual therapy 6. Willingness to be on birth control for women of childbearing age or established postmenopausal for at least 1 year 7. Patients must provide written informed consent after the scope and nature of the investigation has been explained to them. 8. Patients must be considered to be compliant with their usual therapy 9. Patients must provide written informed consent after the scope and nature of the investigation has been explained to them. 10. Patients must be able and willing to comply with the requirements of this study protocol Exclusion Criteria: 1. Women who are pregnant, breast feeding or may be considering pregnancy during the study period 2. Renal impairment as evidenced by a serum creatinine >150 µmol/l or estimated glomerular filtration rate (eGFR) <50mL/min/1.73m2 3. Severe heart failure - systolic or diastolic New York Heart Association Functional classification 3 or 4 4. Moderate or severe valvular heart disease considered likely to require intervention 5. Dependency, frailty or a predicted life expectancy < 5 years 6. Peripheral neuritis, myositis or marked myo-sensitivity to statins 7. Requirement for long term colchicine therapy for any other reason 8. Current enrollment in another trial 9. Patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis) or patients with chronic diarrhea 10. Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study 11. Patient with progressive neuromuscular disease of Creatine Phosphokinase (CPK) level >3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing. 12. Patients already taking long term colchicine therapy for any other reason 13. History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy 14. Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI. 15. Allergy to contrast material

Study Design


Intervention

Drug:
Colchicine 0.5 MG
0.5mg per day of Colchicine orally administered

Locations

Country Name City State
United States Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of change in low attenuation plaque volume as measured by multidetector computed tomography (MDCT) angiography Reduction of low attenuation plaque volume from baseline (start of the study) till the final visit will be measured using Coronary Computed Tomography Angiography (CTA). 12 months
Secondary Effect of Colchicine on markers of inflammation using laboratory tests To determine the effect of Colchicine on markers of inflammation (IL-6, IL-1a, IL-1ß, IL-18 high sensitivity C-reactive protein) 12 months
Secondary Effects of Colchicine on Pericoronary Adipose Tissue (PCAT) volume using CTA To determine the effects of Colchicine on PCAT volume. 12 months
Secondary Effects of Colchicine on Epicardial Adipose Tissue (EAT) volume using CTA To determine the effects of Colchicine on EAT volume. 12 months
Secondary Effect of Colchicine on the markers of Endothelial Function using Flow-mediated dilation (FMD) To determine the effect of Colchicine on Endothelial function using FMD. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A